RT Journal Article SR Electronic T1 Derivo embolization device in the treatment of unruptured intracranial aneurysms: a prospective multicenter study JF Journal of NeuroInterventional Surgery JO J NeuroIntervent Surg FD BMJ Publishing Group Ltd. SP 541 OP 546 DO 10.1136/neurintsurg-2020-016303 VO 13 IS 6 A1 Christian A Taschner A1 Christian Paul Stracke A1 Franziska Dorn A1 Krzysztof Bartosz Kadziolka A1 Kornelia Kreiser A1 László Solymosi A1 Mirko Pham A1 Jan Hendrik Buhk A1 Bernd Turowski A1 Wolfgang Reith A1 Samer Elsheikh A1 Stephan Meckel A1 Hendrik Janssen A1 Alexander Hammer A1 Oliver Beuing A1 Olav Jansen A1 Horst Urbach A1 Michael Knauth A1 Carolin Jenkner A1 René Chapot YR 2021 UL http://jnis.bmj.com/content/13/6/541.abstract AB Background Flow diverters (FD) are used regularly for the endovascular treatment of unruptured intracranial aneurysms. We aimed to assess the safety and effectiveness of the Derivo embolization device (DED) with respect to long-term clinical and angiographic outcomes.Methods A prospective multicenter trial was conducted at 12 centers. Patients presenting with modified Rankin Score (mRS) of 0–1, treated for unruptured intracranial aneurysms with DED were eligible. Primary endpoint was the mRS assessed at 18 months with major morbidity defined as mRS 3–5. Satisfactory angiographic occlusion was defined as 3+4 on the Kamran scale.Results Between July 2014 and February 2018, 119 patients were enrolled. Twenty-three patients were excluded. Ninety-six patients, 71 (74%) female, mean age 54±12.0 years, were included in the analysis. Mean aneurysm size was 14.2±16.9 mm. The mean number of devices implanted per patient was 1.2 (range 1–3). Clinical follow-up at 18 months was available in 90 (94%) patients, resulting in a mean follow-up period of 14.8±5.2 months. At last available follow-up of 96 enrolled patients, 91 (95%) remained mRS 0–1. The major morbidity rate (mRS 3–5) was 3.1% (3/96), major stroke rate was 4.2% (4/96), and mortality was 0%. Follow-up angiographies were available in 89 (93%) patients at a median of 12.4±5.84 months with a core laboratory adjudicated satisfactory aneurysm occlusion in 89% (79/89).Conclusion Our results suggest that DED is a safe and effective treatment for unruptured aneurysms with high rates of satisfactory occlusion and comparably low rates of permanent neurological morbidity and mortality.Trial registration DRKS00006103The data that support the findings of this study are available from the corresponding author upon reasonable request.